2 results match your criteria: "Centre d'information et de soins sur l'immunodéficience humaine (CISIH)[Affiliation]"
[Use of Nadis(®) software to improve adverse drug reaction reporting of antiretroviral drugs: experience in south west of France (midi-pyrénées)].
Therapie
September 2014
Service de Pharmacologie médicale et clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Information sur le Médicament, CHU Toulouse, Inserm U1027, Université Toulouse III, Toulouse, France.
Objectives: To study the value of the module of pharmacovigilance in Nadis® to improve the antiretroviral (ARV) drugs-induced adverse drug reactions (ADRs) reporting.
Methods: We collected the ADRs reported for 17 months from November 2010 until April 2012. Following data were recorded: characteristics of patients, ADRs, ARV drugs.
Predictive factors of treatment interruption duration in a cohort of HIV-1 infected patients with CD4 count greater than 350 cells per mm3.
Med Mal Infect
June 2006
Centre d'information et de soins sur l'immunodéficience humaine (CISIH), hôpital Purpan, place Baylac, 31059 Toulouse cedex, France.
Objective: To determine predictive factors of treatment interruption (TI) duration within a cohort of HIV-1 infected patients having stopped their treatment with CD4 above 350 cells per mm(3).
Design: Data were collected from computerized medical records. Patients were selected if they were HIV-1 positive, 18 years of age or older, and had stopped their treatment between January 1st, 1999 and July 1st, 2003, with CD4 count above 350 cells per mm(3).